Text Size

PULSE WAVE ANALYSIS AND VELOCITY IN PATIENTS WITH CHRONIC RENAL FAILURE

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier:
NCT01579032
First received: April 13, 2012
Last updated: April 16, 2012
Last verified: February 2012
History of Changes
  Purpose

The aims of the presented study are as follows:

  1. To evaluate the endothelial function and arterial stiffness in a large cohort of prevalent CKD patients by means of non-invasive applantion tonometry.
  2. To evaluate the association between the serum levels of the representatives of the various classes of uremic toxins and markers of endothelial function and arterial stiffness.
  3. To evaluate the association between markers of inflammation and oxidative stress and markers of endothelial function and arterial stiffness.
  4. To evaluate the association between echocardiographic parameters and markers of arterial stiffness

Condition
CHRONIC RENAL FAILURE
Left Ventricular Hypertrophy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: PULSE WAVE ANALYSIS AND VELOCITY IN PATIENTS WITH CHRONIC RENAL FAILURE: A CROSS-SECTIONAL OBSERVATIONAL STUDY TO ASSESS ASSOCIATION WITH LEFT VENTRICULAR HYPERTROPY, UREMIC TOXINS AND INFLAMMATION.

Resource links provided by NLM:

MedlinePlus related topics: Kidney Failure
U.S. FDA Resources

Further study details as provided by Universitaire Ziekenhuizen Leuven:

Enrollment: 90
Study Start Date: January 2004
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
CKD patients

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

CKD patients

Criteria

Inclusion Criteria:

  • Age: 18-60
  • Chronic kidney disease: according to the K-DOQI guidelines ( kidney damage ≥ three months, as defined by structural or functional abnormalities of the kidney, with or without decreased GFR, manifest by either: pathological abnormalities; or markers of kidney damage, including damage in the composition of blood or urine test, or abnormalities in imaging tests; GFR< 60 ml/min/1.73m² for ≥ three months, with or without kidney damage)
  • Written informed consent

Exclusion Criteria:

  • major illnesses( life expectancy of < 1 year)
  • history of atrial fibrillation
  • history of myocardial infarction, unstable angina, congestive heart failure, peripheral vascular diasease ,cerebrovascular disease, diabetes

(nonechogenic)

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01579032

Locations
Belgium
University Hospitals
Leuven, Belgium, 3000
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
  More Information

No publications provided

Responsible Party: Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier: NCT01579032     History of Changes
Other Study ID Numbers: ML2863
Study First Received: April 13, 2012
Last Updated: April 16, 2012
Health Authority: Belgium: Ethics Committee

Keywords provided by Universitaire Ziekenhuizen Leuven:
CKD,

Additional relevant MeSH terms:
Hypertrophy
Kidney Failure, Chronic
Renal Insufficiency
Hypertrophy, Left Ventricular
Pathological Conditions, Anatomical
Renal Insufficiency, Chronic
 Kidney Diseases
Urologic Diseases
Cardiomegaly
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 16, 2013